Pharmaceutical Technology

MAY 16, 2023

trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.

Marketing 52

Marketing Sales Pharma Leads 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. The first anti-BCMA product to enter the R/R market was GlaxoSmithKline’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin-blmf), gaining FDA approval in 2020.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Marketing 59

pharmaphorum

OCTOBER 10, 2022

The pharma group said earlier this year it is hoping for eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, and thrombosis as well as PAH, that will swell its sales from in the category to $10 billion around the end of the decade.

Sales 52

Sales FDA Pharma Competition 52

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

PM360

SEPTEMBER 21, 2023

In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

OCTOBER 18, 2022

Akouos has a portfolio of experimental gene therapies led by AK-OTOF, which uses an adeno-associated virus (AAV) vector to a functional copy of the otoferlin (OTOF) gene and was recently approved for clinical testing by the FDA. per month if conditions are not met, until the end of 2028 when they will all expire.

Medicine 52

Medicine FDA Patients Pharma 52

Contrarian Sales Techniques

FEBRUARY 10, 2023

According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028. This growth is driven by several factors, including: 1.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

pharmaphorum

AUGUST 4, 2022

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 The drug is already approved in Japan for ANC vasculitis, but is sold there by Kissei Pharma, while Otsuka has commercial rights to it in Canada. billion bid to buy out the company.

Side effects 98

Side effects Sales Pharma Competition 98

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics).

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52